NIH Highlighted Topic: Novel Circuits and Mechanisms Modulating Sensory Integration and Addiction
Below is a brief summary. Please check the full solicitation before applying (link in resources section).
Executive Summary:
The National Institutes of Health (NIH) is seeking innovative research proposals through the SBIR Program focused on understanding how sensory processing, interoception, and neural reward circuitry contribute to substance use disorders (SUDs) and addiction-related behaviors. NIH is particularly interested in technologies, models, and neuroscience tools that investigate how multisensory integration and subjective reward experiences influence addiction vulnerability, progression, relapse, and recovery.
Traditional addiction research has focused heavily on core reward circuitry, but emerging evidence suggests that sensory processing systems and integrated subjective experiences play a critical role in shaping drug-seeking behavior and loss of cognitive control. NIH is encouraging projects that explore the neural mechanisms linking sensory processing, interoception, synaptic plasticity, and reward contextualization across different stages of substance use disorder progression. Companies developing neurotechnology platforms, AI-enabled neuroscience tools, neuromodulation systems, computational models, imaging technologies, behavioral analytics platforms, or addiction therapeutics may be strong candidates for funding.
NIH is especially interested in projects examining multisensory processing, sensory-evoked neural plasticity, interoceptive signaling, chronic drug exposure effects, withdrawal-associated neural adaptations, and genetic influences on reward processing. Research focused on sex-specific neural mechanisms, personalized addiction interventions, and advanced behavioral models is also encouraged.
Through the NIH SBIR Program, U.S. small businesses may apply for up to $323,090 in Phase I funding and up to $2,153,927 in Phase II funding to support research, development, validation, and commercialization activities. Applications are accepted on January 5th, April 5th, and September 5th annually, with funding typically beginning approximately 9 months after submission.
This highlighted topic is supported primarily by the National Institute on Drug Abuse (NIDA) and the Office of Research on Women’s Health (ORWH), both of which may give special consideration to high-impact applications advancing addiction neuroscience, neuromodulation technologies, sensory processing research, and precision behavioral health solutions.
How much funding would I receive?
Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.
What could I use the funding for?
Funding may support the research, development, validation, and commercialization of technologies and therapeutic approaches focused on addiction neuroscience, sensory integration, and substance use disorder mechanisms.
Eligible activities may include:
Development of neurotechnology platforms for studying reward circuitry and sensory processing
AI and machine learning tools analyzing addiction-related neural activity and behavioral patterns
Neuromodulation technologies targeting sensory-reward neural pathways
Computational neuroscience models evaluating subjective reward processing and addiction progression
Imaging technologies for studying interoception, sensory integration, and synaptic plasticity
Behavioral assessment platforms measuring sensory-evoked responses and motivated behavior
Research investigating neural adaptations associated with acute, chronic, and withdrawal-related drug exposure
Technologies exploring multisensory influences on substance use and relapse vulnerability
Genetic and molecular studies identifying enhancers or suppressors of reward and sensory systems
Precision medicine and personalized intervention approaches for substance use disorders
Sex-specific neuroscience research examining addiction-related neural processing differences
Drug discovery and therapeutic development targeting sensory-reward neural circuits
Digital health tools supporting addiction monitoring, behavioral intervention, and recovery management
Validation studies, translational research, prototype development, and regulatory preparation activities
Commercialization planning and scale-up activities for neuroscience, neurotechnology, and addiction treatment solutions
Funding may also support personnel, laboratory testing, software development, computational infrastructure, prototype fabrication, neuroimaging systems, intellectual property protection, commercialization strategy development, and other research and development activities necessary to advance a commercially viable solution aligned with NIH priorities.
Are there any additional benefits I would receive?
Beyond the formal funding award, awardees gain several strategic advantages:
Government Validation and Credibility:
Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.Enhanced Visibility and Market Recognition:
Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.Access to the Federal Innovation Ecosystem:
Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.Stronger Commercial and Exit Potential:
By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.
What is the timeline to apply and when would I receive funding?
Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.
Where does this funding come from?
Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.
Who is eligible to apply?
Applicants must be U.S. small business concerns (SBCs) that:
Are organized for profit with a U.S. place of business.
Have ≤ 500 employees including affiliates.
Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.
What companies and projects are likely to win?
Projects that demonstrate:
A clear unmet medical or public-health need,
Strong scientific rationale and feasibility,
High commercialization potential, supported by a realistic market and regulatory strategy, and
Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).
Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.
Are there any restrictions I should know about?
Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.
Foreign entities are not eligible.
Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.
How long will it take me to prepare an application?
For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.
How can BW&CO help?
Our team specializes in complex federal R&D proposals and can:
Triple your likelihood of success through proven strategy and insider-aligned proposal development
Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations
Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.
